这种用于降低高胆固醇的常用药物也可以保护肝脏免受侵袭

StephenW

这种用于降低高胆固醇的常用药物也可以保护肝脏免受侵袭性肿瘤的侵害
2022 年 1 月 30 日，詹姆斯·雷诺

研究继续进行药物试验，经常发现某些药物也具有与已知药物不同的作用。在 ProiezionidiBorsa 的页面上，我们已经多次看到药物显示出未知副作用或意外益处的案例。

今天，我们报告在台北的国立台湾大学公共卫生学院进行的权威研究结果。该研究检查了他汀类药物的“副作用”。研究人员会发现，这种用于降低胆固醇的常见药物对我们的身体也有其他好处。特别是，他汀类药物的使用可以在预防攻击肝脏的特定肿瘤方面发挥关键作用。
当肝脏面临肝癌风险时

世界上癌症死亡的第二个原因是肝细胞癌。它是一种特别具有侵袭性的癌症，会影响肝脏。肝癌也是一种特别沉默的肿瘤，处于疾病的早期阶段，因此难以诊断。它通常会出现的第一个症状是：体重减轻、体液潴留、疲劳、食欲不振。

但我们知道有些因素会增加风险。事实上，这种肝癌通常会影响那些已经患有肝硬化、乙型肝炎、丙型肝炎和代谢综合征的人。

台北国立台湾大学公共卫生学院的研究人员首先将注意力集中在患有丙型肝炎的肝脏上。他们的目的是验证使用他汀类药物（一种通常用于降低坏胆固醇的药物）是否可以降低患肝癌的风险。该研究以大量患者样本为参考，收集了我们在下面总结的数据。
这种用于降低高胆固醇的常用药物也可以保护肝脏免受侵袭性肿瘤的侵害

正如预期的那样，一些台湾研究人员研究了他汀类药物对预防肝细胞癌的作用，这是一种影响肝脏的特别侵袭性癌症。研究人员检查了从 1999 年到 2010 年监测的 261,000 名丙型肝炎患者的样本。观察性研究不足以推荐他汀类药物作为治疗此类癌症的合适药物。然而，专家说，他汀类药物的使用似乎与这种特殊肝癌风险的降低相匹配。但还有更多：专家表示，长期使用他汀类药物除了阻止肝癌的形成外，还会限制丙型肝炎病毒的传播。

推荐阅读

使用这些常见抗胆固醇药物的人患前列腺癌的风险会显着降低
（本文中的信息仅供参考，不能以任何方式替代医疗建议和/或专家的意见。此外，它不构成制定诊断或治疗处方的要素。为此无论如何，建议您始终寻求医生或专家的意见，并阅读有关本文的警告以及可以咨询的作者责任。这里”）

StephenW

This common drug used to lower high cholesterol would also protect the liver from an aggressive tumor
January 30, 2022 by James Reno

Research continues drug trials, often discovering that some drugs also have different effects than known ones. We have already seen several times, on the pages of ProiezionidiBorsa, cases in which a drug reveals unknown side effects or unexpected benefits.

Today we report the findings of authoritative research conducted at the National Taiwan University College of Public Health in Taipei. The research examines the “side effects” of statins. Researchers would have found that this common drug used to lower cholesterol would also have other benefits for our body. In particular, the use of statins could play a key role in preventing a particular tumor that attacks the liver.
When the liver risks hepatocarcinoma

The second cause of cancer death in the world is represented by hepatocellular carcinoma. It is a particularly aggressive form of cancer, which affects the liver. Hepatocarcinoma is also a particularly silent tumor, in the early stages of the disease, therefore difficult to diagnose. The first symptoms with which it can usually occur are: weight loss, fluid retention, fatigue, loss of appetite.

But we know that there are factors that increase the risk. In fact, this liver cancer often affects those already suffering from cirrhosis, hepatitis B, hepatitis C and metabolic syndrome.

Researchers at the National Taiwan University College of Public Health in Taipei focused their attention above all on livers with hepatitis C. Their intent was to verify whether the use of statins, a drug usually used to lower bad cholesterol, could reduce the risk of hepatocarcinoma. The research took as a reference a large sample of patients, collecting the data that we summarize below.
This common drug used to lower high cholesterol would also protect the liver from an aggressive tumor

As anticipated, some Taiwanese researchers have studied the effect of statins on the prevention of hepatocellular cancer, a particularly aggressive cancer that affects the liver. The researchers examined a sample of 261,000 hepatitis C patients, monitored from 1999 to 2010. The observational study is not sufficient to recommend statins as a suitable drug for treating this type of cancer. However, experts say, statin use appears to match a reduction in the risk of this particular liver cancer. But there is more: experts say that prolonged use of statins, in addition to discouraging the formation of liver cancer, would also limit the hepatitis C virus.

Recommended reading

The risk of prostate cancer would decrease dramatically in those who use these common anti-cholesterol drugs
(The information in this article is for informational purposes only and does not in any way substitute for medical advice and / or the opinion of a specialist. Furthermore, it does not constitute an element for formulating a diagnosis or for prescribing a treatment. For this reason it is recommended, in any case, to always seek the opinion of a doctor or a specialist and to read the warnings regarding this article and the author’s responsibilities which can be consulted. HERE”)